Cerenome shares interim Phase 1 safety data for REYOBIQ in leptomeningeal metastases

Cerenome Inc. presented interim results from its Phase 1 ReSPECT‑LM study of the radiopharmaceutical REYOBIQ at the Society for Neuro‑Oncology meeting on November 13, 2026. Among the first ten patients treated with repeated intraventricular dosing, no dose‑limiting toxicities were observed and only one Grade 3 treatment‑related nausea event occurred, which resolved in five days. No leptomeningeal progression was seen at the three‑ and six‑month assessments (0/5 patients), while one of four evaluable patients progressed by nine months. The company said it will pursue a randomized Phase 2 trial in 2027, subject to continued clinical progress and regulatory alignment.

TipRanks’ Spark notes a Neutral rating for CNSY, citing weak financial performance despite the positive safety data (the most recent analyst rating is a Buy with a $12.00 price target). The interim safety profile supports the planned Phase 2 study in 2027, which could be a catalyst for the stock if the trial proceeds as expected.

  • 1The interim data were presented on November 13, 2026 at the Society for Neuro‑Oncology annual meeting.
  • 2Ten patients received repeated intraventricular REYOBIQ dosing in the Phase 1 ReSPECT‑LM study.
  • 3No dose‑limiting toxicities or treatment‑related discontinuations were reported.
  • 4One patient experienced Grade 3 treatment‑related nausea that resolved within five days.
  • 5Median within‑patient variation in repeat‑dose absorbed dose per mCi was 8%.
  • 6No leptomeningeal progression was documented at three or six months (0/5 evaluable patients).

Sources